March 2002
A while back we published a story about a Navy research program that
produced promising results for hearing loss prevention and treatment.
American BioHealth Group has licensed that technology and plans to bring
it to market! This could be the most exciting hearing loss news in a
long time!
For additional information, please contact:
David Karlman
American BioHeath Group, LLC
11808 Rancho Bernardo Road, Ste. 151
San Diego, California 92128
Investor Relations Department
Industrial_Relations@ABGPharma.com
858-675-3600
Here are portions of the press release.
~~~~~~~~~~~~~~~~~~~
American BioHealth Group, LLC has signed an exclusive license with
the United States Navy for a new and novel pharmaceutical technology
developed by the Naval Medical Center-San Diego for the prevention and
treatment of hearing loss resulting from noise and chemical exposure.
The technology, a family of unique antioxidant compounds, has been
shown to effectively prevent and restore hearing loss in animal models
exposed to various noise insults and cancer therapies. This was
developed under the direction of Army Colonel Richard D. Kopke, MD, by
researchers at Naval Medical Center-San Diego, and researchers at the
State University of New York at Buffalo. This pharmaceutical development
promises to aid tens of millions of Americans at risk for sensorineural
hearing loss.
"This is a seminal moment for the 39 million plus individuals
that are at risk and suffer from hearing loss due to noise or chemical
exposure," said David Karlman, Chairman and Chief Executive Officer
of American BioHealth Group, LLC. "Dr. Kopke's team of talented
researchers have committed years to the specific discipline of finding a
cure for sensorineural hearing loss. This agreement further verifies the
magnitude of their contribution and will result in needed pharmaceutical
products to help tens of millions of Americans who today have no
pharmaceutical treatment options for the prevention or restoration of
sensorineural hearing loss. We are honored to be the organization chosen
to work with the Naval Medical Research Center in San Diego, Dr. Kopke,
and the Office of Naval Research to bring this exciting research to
commercialization."
Under the terms of the exclusive license agreement, American
BioHealth Group will conduct clinical research, product development and
have an exclusive license to market the products for the protection and
restoration of hearing loss. The compounds that will be developed and
commercialized by American BioHealth Group have already been approved by
the FDA for other indications and have acceptable, well-proven safety
profiles.
Mark Mugerditchian, President and Chief Operating Officer states,
"For the first time, physicians will be able to treat individuals
suffering from sensorineural hearing loss using a pharmaceutical product
that has gone through the rigorous safety and efficacy testing required
by FDA. We believe that our first product, once approved, will be the
first pharmaceutical product in the marketplace targeted at these
indications. Our goal is to develop a series of products based on this
technology, that addresses this significant unmet medical need."
American BioHealth Group, LLC, is a pharmaceutical company that
conducts research, development, sales, and marketing of health care
products that improve the quality of life for patients suffering from
chronic, or potentially chronic hearing disorders.
